SubjectWell and Reify Health have announced the results from a recent survey of clinical trial health and safety protocols amidst COVID-19. The joint survey sought to understand how sites are updating protocols to better protect patients in the face of the ongoing pandemic, including both COVID-19- and non-COVID-19-related clinical trials.
SubjectWell and Reify Health polled 268 clinical trial site partners in the U.S. and found that the vast majority of these sites have implemented multiple measures in response to the continued spread of novel coronavirus. Nearly all sites (96%) reported an increase in sanitation procedures, and almost all have implemented protocols to keep infected patients at home and infected staff out of the office (91% and 93%, respectively).
An overwhelming majority of sites also reported a variety of other patient health protocols on site to ease patients' hesitations before and upon arrival at the location:
“We are in the midst of, arguably, the most challenging impediment to clinical research in recent memory, and conducting ongoing research safely is paramount. Although clinical trial awareness is at an all-time high, we must look at the inevitable increase of patients’ concerns and hesitations as well,” said Ivor Clarke, CEO, SubjectWell. “The data from our joint survey with Reify Health shows it’s critical for sites to go above and beyond to ease these concerns throughout every step of the patient recruitment and clinical trial process. As our company continues to connect thousands of patients with research sites and sponsors to clinical research, we’ll work in tandem with these sites to understand how they operate and which safety practices are being enforced, allowing us to confidently move forward in the fight against COVID-19 and treat our patients like customers, ensuring their needs are met from the moment we connect with them.”
For more of the survey’s findings, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Empower Sponsor Success with Insights from Sites
October 3rd 2024Are you tired of clinical trial technology that slows down processes? Are your sites looking for more intuitive solutions? At YPrime, we’ve taken a deep dive into site experiences and perspectives, sharing ways to bridge the gap between sponsors, sites, and patients, to foster a more efficient clinical trial process.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
New Survey Uncovers Distrust as Key Factor in Enrollment Declines Among Black Patients
October 2nd 2024Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.
Tulisokibart Shows Superior Efficacy in Achieving Clinical Remission for Ulcerative Colitis Patients
October 2nd 2024Proof-of-concept Phase II ARTEMIS-UC trial shows efficacy of investigational humanized monoclonal antibody tulisokibart in treating inflammatory bowel disease compared with placebo.